Latest Regenerative Medicine News

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

Osteopore Limited reports a three-fold increase in craniofacial implant sales within a year of signing an exclusive distribution deal with Zimmer Biomet, signaling strong early traction across key global markets.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.

Orthocell has achieved a significant milestone by recording its first US sales revenue for Remplir™, its flagship nerve repair product, shortly after FDA clearance and initial surgical use.

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.

Cambium Bio has secured ethics approvals in Australia and the US to initiate pivotal Phase 3 trials of Elate Ocular, targeting moderate to severe dry eye disease, with patient dosing expected in October 2025.

Orthocell’s new study confirms Remplir™ delivers superior nerve regeneration and faster muscle recovery compared to traditional sutures, bolstering its US market rollout plans.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

Osteopore Limited has drawn down an additional A$500,000 from the first tranche of its redeemable convertible notes, bringing total subscriptions close to the A$5 million tranche limit. The funds will support ongoing operations and future growth initiatives.

Osteopore Limited has increased its capital raise by drawing down an additional A$500,000 on its Tranche 1 redeemable convertible notes, bringing total subscriptions to A$3.5 million. The funds will support ongoing operations and future growth initiatives.